The inhibition of RAS with ACE inhibitors (ACEi) and AngII receptor blockers (ARB) is a cornerstone in the management of patients with chronic kidney disease (CKD), presenting additional kidney protection beyond their blood pressure (BP)-lowering effect [5,6]. This evidence concerns the gene ACE and chronic kidney disease.